Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Assets
Cash and cash equivalents	$ 1,393,474	$ 1,980,015
Accounts receivable
Inventory		22,666
Advance to related party		58,135
Prepaid expense and other current assets	64,493	23,635
Total current assets	1,457,967	2,084,451
Patents, net	173,179	182,386
Property and equipment, net	18,389	26,997
Total assets	1,649,535	2,293,834
Liabilities and Stockholders' Deficit
Accounts payable and accrued expenses	188,251	159,300
Advances from investors	301,773	777,258
Convertible notes payable – related party	513,356	886,481
Total current liabilities	1,003,380	1,823,039
Total liabilities	1,003,380	1,823,039
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.01 par value: Authorized shares - 10,000,000, Issued and outstanding shares – 0 at June 30, 2018 and December 31, 2017
Common stock, $0.01 par value: Authorized shares - 100,000,000, Issued and outstanding shares – 34,674,261 and 23,156,563 at June 30, 2018 and December 31, 2017, respectively	346,742	231,565
Additional paid-in capital	2,691,661	2,123,205
Accumulated deficit	(2,450,101)	(1,883,975)
Total Amarillo Bioscience’s Inc. equity	588,302	470,795
Non-controlling interests	57,853
Total stockholders’ equity	646,155	470,795
Total liabilities and stockholders’ equity	$ 1,649,535	$ 2,293,834